Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Bayer wins new uses for Eylea, Stivarga
Bayer wins extra indications for Eylea and Stivarga in the US and EU; new Novo diabetes play combines insulin and Victoza; Novartis gets nod for glaucoma combo.
Special Feature
Top companies stabilise out of downward trend
The downward trend for the majority of top ten originator companies evident in 2012-13 steadied during the last financial year as most held their rankings on the basis of MAT PBS income.
Working Life
Why reg affairs folks love their jobs
A British study of 274 occupations shows quality assurance and regulatory professionals rank number five when it comes to salary and job satisfaction. Karen Keast takes a look at reg affairs at Bayer and finds there's much more to the role than product registration.
Approvals Action
Janssen's hep C drug approved
Janssen has won market approval for new hepatitis C drug Olysio, which was considered by the PBAC for reimbursement earlier this month, while more competitors have been registered for Roche's Xeloda.
Open Forum
Time to renew commitment on HIV/AIDS
Former High Court Judge, the Honorable Michael Kirby opened the 20th International AIDS Conference in Melbourne by urging the HIV/AIDS community, governments and the public "never to be content while anyone is at risk of being left behind".